Leading the Fight to treat and cure
Tay-Sachs, Canavan, Sandhoff, GM1 and related diseases

NTSAD Webinars

NTSAD officially has launched a webinar series to bring the experts to the community to discuss topics ranging from research advances to issues that impact the family.

Thursday, January 23, 2020

 

Who is the FDA and what do they do?

Presenter:

Curtis Scribner, MD
Independent Biotech Pharma Regulatory and Clinical Consultant

The goal of this webinar is to inform the NTSAD community about the regulatory side of clinical trials. We are grateful to Dr. Curt Scribner for lending his time and sharing his expertise with the NTSAD community to shed light on the what, how and why behind the process of a clinical trial's approval.

Friday, December 6, 2019

 

 

What is a Clinical Trial: Demystifying the Process

Presenter:

Gerald Cox, MD, PhD
NTSAD Board Member
Boston Children's Hospital

Outline:
What is a clinical trial and what do they involve?
What are the different types of clinical trials?
Who oversees clinical trials?
FDA oversees each step of the drug development
How do I know if I or my child is eligible for a clinical trial?
How much does it cost to participate in a clinical trial?

Glossary of Terms here.

Wednesday, August 7, 2019

 

 

IntraBio and IB1001 Clinical Trials 

Panelists:

Taylor Fields, Senior VP, IntraBio
Tatiana Bremova, MD, PhD, University Hospital Bern, Switzerland

A presentation about IntraBio's compound, IB1001, the clinical trials in the US and Europe, and the hope that it has a positive impact on the GM2 Gangliosidoses (Tay-Sachs and Sandhoff). Facilitated by Staci Kallish, DO, NTSAD Board president.

pdf Acetyl-DL-leucine in Niemann-Pick (Type C) - paper (587 KB)

pdf Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials - paper (2.91 MB)

 


Is there a particular topic you'd like to see discussed in a webinar format? Feel free to send an email to NTSAD This email address is being protected from spambots. You need JavaScript enabled to view it..

Login